Filing Details

Accession Number:
0001179110-11-002747
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-02-15 15:53:38
Reporting Period:
2011-02-11
Filing Date:
2011-02-15
Accepted Time:
2011-02-15 15:53:38
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
815094 Abiomed Inc ABMD Surgical & Medical Instruments & Apparatus (3841) 042743260
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1021038 A Henri Termeer C/O Abiomed, Inc.
22 Cherry Hill Drive
Danvers MA 01923
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.01 Par Value Disposition 2011-02-11 15,000 $13.52 1,881,231 No 4 S Indirect by Genzyme Corporation
Common Stock, $0.01 Par Value Disposition 2011-02-14 10,000 $13.48 1,871,231 No 4 S Indirect by Genzyme Corporation
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect by Genzyme Corporation
No 4 S Indirect by Genzyme Corporation
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock, $0.01 Par Value 60,100 Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Stock Option (right to buy) $19.69 2001-08-09 2010-08-09 5,000 5,000 Direct
Common Stock Stock Option (right to buy) $18.40 2002-08-08 2012-08-08 5,000 5,000 Direct
Common Stock Stock Option (right to buy) $4.71 2003-08-06 2013-08-06 5,000 5,000 Direct
Common Stock Stock Option (right to buy) $5.15 2004-08-13 2014-08-13 5,000 5,000 Direct
Common Stock Stock Option (right to buy) $10.41 2005-08-11 2014-08-11 8,000 8,000 Direct
Common Stock Stock Option (right to buy) $10.06 2006-08-09 2015-08-10 8,000 8,000 Direct
Common Stock Stock Option (right to buy) $13.21 2007-08-08 2016-08-09 8,000 8,000 Direct
Common Stock Stock option (right to buy) $12.69 2008-08-13 2017-08-08 8,000 8,000 Direct
Common Stock Stock Option (right to buy) $18.63 2009-08-12 2018-08-13 8,000 8,000 Direct
Common Stock Stock Option (right to buy) $7.67 2010-08-11 2019-08-12 12,000 12,000 Direct
Common Stock Stock Options (right to buy) $9.99 2011-08-10 2020-08-11 12,000 12,000 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2010-08-09 5,000 5,000 Direct
2012-08-08 5,000 5,000 Direct
2013-08-06 5,000 5,000 Direct
2014-08-13 5,000 5,000 Direct
2014-08-11 8,000 8,000 Direct
2015-08-10 8,000 8,000 Direct
2016-08-09 8,000 8,000 Direct
2017-08-08 8,000 8,000 Direct
2018-08-13 8,000 8,000 Direct
2019-08-12 12,000 12,000 Direct
2020-08-11 12,000 12,000 Direct
Footnotes
  1. Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 1989 Non-Qualified Stock Option Plan for Non-Employee Directors.
  2. This option becomes exercisable in full on the date set forth in Table II, Column 6.
  3. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for the purposes of Section 16 or for any other purposes. The reporting person is the Chief Executive Officer of Genzyme Corporation.
  4. Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2000 Stock Incentive Plan.
  5. Grant to reporting person of option to buy shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan.
  6. This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $13.42 and $13.65. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
  7. This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $13.45 and $13.53. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.